ReviewInternational journal of molecular sciences2022
Neurogenesis as a Tool for Spinal Cord Injury.
Review in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 20 citations in OpenAlex.
- Harnessing Endogenous Neural Stem Cells: A New Frontier in Spinal Cord Injury Repair.Neurochemical research · 2026Review
- An electrochemical sensor for detecting IL-6 expression following spinal cord injury.RSC advances · 2025Article
- Ptbp1 knockdown induces conversion of rat spinal cord astrocytes into neuron like cells.Scientific reports · 2025Article
- Research progress on the mechanisms of endogenous neural stem cell differentiation in spinal cord injury repair.Frontiers in cellular neuroscience · 2025Review
- Unravelling the Road to Recovery: Mechanisms of Wnt Signalling in Spinal Cord Injury.Molecular neurobiology · 2024Review
- Regeneration and Plasticity Induced by Epidural Stimulation in a Rodent Model of Spinal Cord Injury.International journal of molecular sciences · 2024Article
- Metformin enhances endogenous neural stem cells proliferation, neuronal differentiation, and inhibits ferroptosis through activating AMPK pathway after spinal cord injury.Journal of translational medicine · 2024Article
- Recent advances in endogenous neural stem/progenitor cell manipulation for spinal cord injury repair.Theranostics · 2023Review
- Reprogramming stem cells in regenerative medicine.Smart medicine · 2022Review
- Application and prospects of somatic cell reprogramming technology for spinal cord injury treatment.Frontiers in cellular neuroscience · 2022Review
- The roles and applications of neural stem cells in spinal cord injury repair.Frontiers in bioengineering and biotechnology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Spinal cord injury is a devastating medical condition with no effective treatment. One approach to SCI treatment may be provided by stem cells (SCs). Studies have mainly focused on the transplantation of exogenous SCs, but the induction of endogenous SCs has also been considered as an alternative. While the differentiation potential of neural stem cells in the brain neurogenic regions has been known for decades, there are ongoing debates regarding the multipotent differentiation potential of the ependymal cells of the central canal in the spinal cord (SCECs). Following spinal cord insult, SCECs start to proliferate and differentiate mostly into astrocytes and partly into oligodendrocytes, but not into neurons. However, there are several approaches concerning how to increase neurogenesis in the injured spinal cord, which are discussed in this review. The potential treatment approaches include drug administration, the reduction of neuroinflammation, neuromodulation with physical factors and in vivo reprogramming.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.